Atara Biotherapeutics Receives $38,500,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c4d30543-7d31-449a-83e2-da4114869d48 - Date
12/18/2013 - Company Name
Atara Biotherapeutics - Mailing Address
2659 Townsgate Road Thousand Oaks, CA 91361 - Company Description
Our mission is to develop novel treatment options for patients with severe and life-threatening conditions that have been underserved by scientific innovation. We are investigating therapies targeting unique pathways to pause or reverse patients’ underlying diseases. - Website
http://www.atarabio.com - Transaction Type
Venture Equity - Transaction Amount
$38,500,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds will be used to accelerate the clinical development of Atara’s two lead programs, PINTA 745 and STM 434, which are expected to generate new clinical data within the next 18 months. - M&A Terms
- Venture Investor
Amgen Ventures - Venture Investor
Celgene - Venture Investor
Alexandria Real Estate Equities - Venture Investor
DAG Ventures - Venture Investor
Domain Associates - Venture Investor
Kleiner Perkins Caufield & Byers
